Congestive Heart Failure, Cardiac Effects and Drug Interactions
If signs or symptoms of congestive heart failure occur during administration of SPORANOX® (itraconazole) Oral Solution, continued SPORANOX® use should be reassessed. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions, ADVERSE REACTIONS: Post-marketing Experience, and CLINICAL PHARMACOLOGY: Special Populations for more information.)
Coadministration of the following drugs are contraindicated with SPORANOX® Oral Solution: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin and, in subjects with renal or hepatic impairment, colchicine. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. See CONTRAINDICATIONS and WARNINGS Sections, and PRECAUTIONS: Drug Interactions Section for specific examples.
SPORANOX® is the brand name for itraconazole, an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers.
SPORANOX® (itraconazole) Oral Solution is indicated for the treatment of oropharyngeal and esophageal candidiasis.
(See CLINICAL PHARMACOLOGY: Special Populations, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Published Studies Related to Sporanox (Itraconazole)
Itraconazole vs. trimethoprim-sulfamethoxazole: A comparative cohort study of 200
patients with paracoccidioidomycosis. 
Paracoccidioidomycosis (PCM) is a systemic mycosis endemic to Latin America. Brazil accounts for approximately 80% of cases, where it represents a major
public health issue due to its disabling impact and the number of premature
deaths it causes... Although the results of this study show that
itraconazole was the best treatment option for PCM patients, a double-blind,
randomized, controlled trial is necessary to confirm this conclusion.
Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. [2011.08]
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks...
Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. [2011.05]
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. OBJECTIVE: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis... CONCLUSION: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. [2011.04]
OBJECTIVE: To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers... CONCLUSION: Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered. Copyright (c) 2011 John Wiley & Sons, Ltd.
Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. [2011.03]
PURPOSE: The risk of invasive fungal infection is greater for allogeneic hematopoietic stem cell transplantation (HSCT) than for autologous transplantation. Therefore, many transplantation centers use antifungal prophylaxis for allogeneic HSCT, however, there exists no standard guidelines or consensus regarding autologous HSCT... CONCLUSION: Although beneficial effects such as a shorter duration of fever and reduced need for antibiotic use were observed in the prophylaxis group, the results were not sufficient to draw a definite recommendation about the routine use of antifungal prophylaxis in pediatric autologous HSCT recipients with high-risk solid tumors (Trial registration: NCT00336531).
Clinical Trials Related to Sporanox (Itraconazole)
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. [Completed]
Onychomycosis is a common condition accounting for approximately half of all nail disorders.
It is most commonly caused by dermatophytes. Itraconazole has been approved for the
treatment of onychomycosis in the United States with an approved dosage regimen for the
treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of
itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200
mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This
clinical trial will compare the efficacy and safety of this new tablet formulation with
itraconazole capsules and placebo.
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants [Completed]
The purpose of this observational study is to investigate whether a sufficient concentration
of itraconazole can influence disappearance of a fever (defeverscence) when intravenous
(into the vein) itraconazole is administered for resolving unknown neutropenic fever of
participants who are given itraconazole oral solution as a prophylaxis under general
Concentration of Itraconazole Solution in Nasal Secretions [Completed]
The primary objective of this study is to determine the concentration of itraconazole
irrigation in nasal mucous specimens via collection and High-performance liquid
chromatography (HPLC) assay.
Eight (8) patients with chronic rhinosinusitis (CRS) and two (2) healthy controls will be
enrolled in the initial evaluation. After an initial control nasal specimen, followed by
seven days of twice daily topical itraconazole irrigation, nasal specimens will be collected
at varying time intervals and the concentrations measured.
The primary endpoint is development of a reliable collection and assay technique with
concentration curves over time of topically administered itraconazole. A secondary endpoint
is to determine if the concentrations measured achieve a mean inhibitory concentration
(MIC90) to commonly cultured fungal species in the nose.
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma [Recruiting]
This study will assess the effect of multi-dose administration of itraconazole on the
single-dose pharmacokinetics (PK) of alisertib.
A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers [Not yet recruiting]
Reports of Suspected Sporanox (Itraconazole) Side Effects
Oedema Peripheral (7),
Drug Ineffective (5),
Cardiac Failure Congestive (5),
Self Injurious Behaviour (5),
Diabetes Mellitus (4),
Erectile Dysfunction (4), more >>
Page last updated: 2014-11-30